Ichor Medical Systems Incorporated
11
0
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Combinatorial Therapy to Induce an HIV Remission
Role: collaborator
Combination HTNV and PUUV DNA Vaccine
Role: collaborator
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Role: collaborator
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
Role: collaborator
Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults
Role: collaborator
Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers
Role: lead
Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
Role: collaborator
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
Role: collaborator
Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer
Role: lead
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
Role: lead
Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers
Role: collaborator
All 11 trials loaded